Business Context and Reporting Period
Company: Biogen Idec Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Overview: Biogen Idec is a global biotechnology company focused on neurology, oncology, and immunology. The company markets four primary products: AVONEX (multiple sclerosis), RITUXAN (oncology and rheumatoid arthritis), TYSABRI (multiple sclerosis and Crohn's disease), and FUMADERM (psoriasis). The company operates as a single segment and relies heavily on collaborations, particularly with Genentech for RITUXAN and Elan for TYSABRI.
Key Financial Metrics
| Metric | 2008 | 2007 | 2006 |
|---|---|---|---|
| Total Revenues | $4,097.5 million | $3,171.6 million | $2,683.0 million |
| Net Income | $783.2 million | $638.2 million | $217.5 million |
| Diluted EPS | $2.65 | $1.99 | $0.63 |
| Operating Cash Flow | $1,566.5 million | $1,020.6 million | $841.3 million |
| Total Debt (Outstanding) | $1,113.1 million | $1,563.0 million | N/A |
| Cash & Marketable Securities | $2,262.8 million | $2,115.8 million | $2,314.9 million |
| Working Capital | $1,534.8 million | $179.2 million | N/A |
Revenue Breakdown (2008): Product revenues were $2,839.7 million (69.3%), Unconsolidated Joint Business (primarily RITUXAN) was $1,128.2 million (27.5%), and Other Revenues were $129.6 million (3.2%).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 29.2% year-over-year, driven by a 32.9% increase in product revenues and a 21.8% increase in joint business revenues.
- AVONEX: Revenue grew 18.0% to $2,202.6 million due to price increases and favorable exchange rates.
- TYSABRI: Revenue surged 156.0% to $588.6 million due to increased unit shipments and global expansion.
- RITUXAN (Joint Business): Revenue grew 21.8% to $1,128.2 million, driven by increased sales in oncology and rheumatoid arthritis.
- Expense Increases:
- R&D Expenses: Increased 15.9% to $1,072.1 million, primarily due to advancing pipeline products into Phase 3 trials (e.g., BG-12, Lixivaptan) and a $31.5 million opt-in payment for the GA101 program.
- SG&A Expenses: Increased 19.2% to $925.3 million, driven by international sales and marketing expansion for AVONEX and TYSABRI.
- Debt Restructuring: The company issued $1 billion in Senior Notes (6.0% due 2013 and 6.875% due 2018) in March 2008 to repay a $1.5 billion term loan facility used for a 2007 tender offer. Total debt decreased from $1.56 billion in 2007 to $1.11 billion in 2008.
- Investment Impairments: Recorded $60.3 million in impairment charges on investments in 2008, primarily related to non-agency mortgage and asset-backed securities and strategic investments.
Guidance, Outlook, and Risks
- Outlook: Management expects R&D expenses to increase in 2009 due to a greater number of late-stage clinical trials. SG&A expenses are not expected to increase significantly compared to 2008.
- RITUXAN Royalty Expiration: The company expects a significant decrease in royalty revenues from RITUXAN sales outside the U.S. and Canada beginning in the latter half of 2009. Royalty periods for France, Spain, Germany, and the U.K. expire in 2009. 2009 royalty revenue is projected to be between $250.0 million and $290.0 million.
- TYSABRI Safety: Five confirmed cases of Progressive Multifocal Leukoencephalopathy (PML) have been reported since the product's reintroduction. The company continues to monitor this risk, which could impact market acceptance and sales.
- Manufacturing: A large-scale biologic manufacturing facility in Hillerød, Denmark, is under construction and expected to be ready for commercial production in 2010. Success depends on the completion of the facility and continued demand for TYSABRI.
- Legal Proceedings: The company is involved in various litigation matters, including an arbitration with Genentech regarding the RITUXAN collaboration agreement and change-of-control provisions, and multi-district litigation regarding Medicaid reimbursement reporting.
Key Facts for Investor Verification
- Revenue Concentration: AVONEX and RITUXAN represented approximately 81% of total revenues in 2008. The business is heavily dependent on these two products.
- Collaboration Dependencies: Significant revenue is derived from unconsolidated joint businesses (Genentech for RITUXAN, Elan for TYSABRI). Changes in profit-sharing formulas or collaboration terms could materially impact results.
- Patent Expirations: Key patents for RITUXAN in Europe expire in 2013, and royalty periods for RITUXAN in major European markets expire in 2009-2010.
- Investment Portfolio Risk: The company holds a significant portfolio of marketable securities ($2.26 billion). The 2008 financial market instability resulted in $60.3 million in impairment charges, and further declines could impact earnings.
- Share Repurchases: The company repurchased approximately 12.8 million shares for $738.9 million in 2008. Approximately 6.0 million shares remain available for repurchase under the current program.